RESEARCH (Recognized effect of Statin and ezetimibe therapy for achieving LDL-C Goal), a randomized, doctor-oriented, multicenter trial to compare the effects of higher-dose statin versus ezetimibe-plus-statin on the serum LDL-C concentration of Japanese type-2 diabetes patients design and rationale

Takeshi Inazawa¹, Kentaro Sakamoto², Takahide Kohro³, Raisuke Iijima², Toru Kitazawa⁴, Tsutomu Hirano⁵, Mitsunobu Kawamura⁶, Motoki Tagami⁷, Akira Tanaka⁸, Yasumichi Mori⁹, Tsutomu Yamazaki¹⁰, Teruo Shiba²,¹¹* and the RESEARCH Study Group

Abstract

Aims: Hypercholesterolemia coexisting with diabetes still requires clinical intervention to manage the high risk of cardiovascular disease it poses. No second-step strategy is established, however, for cases where strong statins fail to bring cholesterol down to target levels. In this study we seek to demonstrate the superior effect of ezetimibe in combination with strong statins to reduce LDL-C in Japanese patients suffering from both T2DM and hyper LDL-cholesterolemia.

Methods: T2DM outpatients (109 patients from 16 institutes) who failed to achieve the target LDL-C value were recruited and randomly assigned to two groups, a double-dose-statin group and ezetimibe-plus-statin group. Follow-ups were scheduled at 0, 12, 26, and 52 weeks. The primary endpoint was the percentage change in the level of LDL-C from baseline to 12 weeks.

Interim results: We could successfully create randomized (gender, age, LDL-C, HbA1c, etc.) two groups except for slight differences in apolipoprotein-B and sd-LDL.

Conclusions: RESEARCH is the first prospective, parallel-group, multicenter study comparing a double dose of strong statin with ezetimibe plus strong statin for T2DM patients. The RESEARCH study will provide reliable evidence with which to establish a clinical strategy for diabetics who fail to achieve the target LDL-C value.

Keywords: Hypercholesterolemia, Ezetimibe, Statin

* Correspondence: teruo.shiba@med.toho-u.ac.jp
²Toho University Ohashi Medical center, Tokyo, Japan
¹¹Mitsui Memorial Hospital, Tokyo, Japan
Full list of author information is available at the end of the article

© 2013 Inazawa et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background
The incidence of metabolic disease, a condition often associated with coronary artery disease (CAD) or stroke, is increasing substantially all over the world. According to a Japanese government publication from 2010, some 17.4 million cases of diagnosed or suspected diabetes were reported in the country, about 31.4% more than the number reported in the earlier surveillance from 2002 [1]. Among them, patients with diabetes mellitus face a strong risk of both CAD and stroke. JDCS [2], a cohort study of Japanese type 2 (T2) diabetics, reported a CAD incidence of 9.6/1,000 T2DM patients/year and a stroke incidence of 7.5/1,000 T2DM patients/year. The Hisayama Study [3], another Japanese cohort study, respectively showed CAD and stroke incidences of 8.0 and 10.2 /1000 persons/year in type 2 diabetic patients, versus incidences of 3.4 and 4.0/1,000 persons/year in subjects with normal glucose tolerance. According to those data, Japanese diabetics were exposed to a two-fold higher risk of cardiovascular disease than subjects with normal glucose tolerance.

The risk of cardiovascular disease in diabetes mellitus is pushed sharply higher by hypercholesterolemia, especially elevated low-density lipoprotein cholesterol (LDL-C). Apart from dietary and lifestyle intervention, hydroxymethylglutarylcoenzyme-A -reductase -inhibitors (statins) have been the primary component of LDL-C-lowering therapy. The MEGA study [4], a randomized controlled trial from Japan, has shown that LDL-C reduction by pravastatin reduces the incidences of CAD and stroke in Japanese subjects, effectively duplicating the results by pravastatin reduces the incidences of CAD and stroke reported in the earlier surveillance from 2002 [1].

Methods/design
The RESEARCH study is a prospective, randomized, parallel-group, active-controlled, doctor-oriented, multicenter, clinical trial designed to examine whether ezetimibe combined with a regular dose of strong statin significantly lowers the serum LDL-C concentration in Japanese T2DM patients, compared with a double dose of strong statin administered without ezetimibe.

The study is conducted and managed with the approval of the ethics committee at each institute and conforms closely with the Declaration of Helsinki and the guidelines from the Japanese Ministry of Health, Labor and Welfare (complete revision on December 28, 2004). The protocol has been registered in the UMIN Clinical Trials Registry (UMIN000002593) [13].

Patients
Entry criteria and exclusion criteria are shown in Table 1. The patients enrolled in this study were T2DM outpatients who had failed to achieve the LDL-C target recommended by the Japanese guideline, namely, LDL-C < 120 mg/dL for patients without CAD or LDL-C < 100 mg/dL for patients with CAD [14], in spite of receiving strong statin treatment at the standard dose according to Japan's national health insurance policy (10 mg/day of atorvastatin or 1 mg/day of pitavastatin). Changes in LDL-C values were examined using Friedewald's formula, so patients with hypertriglyceridemia of over 400 mg/dL had to be excluded.

Patients who provided informed consent were randomly assigned to two groups, a double-dose-statin (DS) group and ezetimibe-plus-statin (ES) group. The patients were randomized through a system for online central registration. To reduce heterogeneity between groups, dynamic allocation was adopted using age and gender as

| Entry criteria | Exclusion criteria |
|----------------|-------------------|
| Japaneseess | Pregnant, possible to become pregnant, or breast-feeding to baby(s) |
| Type 2 diabetes mellitus | Hypersensitive to the medicines concerned |
| Age ≥ 20 years | Liver dysfunction |
| Using atorvastatin 10 mg/day or pitavastatin 1 mg/day for > 1 month | HbA1C ≥ 9.4% |
| LDL-C ≥ 120 mg/dL for patients without CAD , LDL-C ≥ 100 mg/dL for patients with CAD | Serum creatinine ≥ 2.0 mg/dL |
| Triglyceride ≥ 400 mg/dL | Secondary dyslipidemia, drug-induced dyslipidemia |
| Homozygotic familial hypercholesterolemia | Other non-specific reason, such as poor adherence |

CAD: coronary artery disease.
assignment factors. The results of the randomization were open to both the patients and doctors.

**Treatments and data collection (Figure 1)**

The patients assigned to the DS group are given double the basal dose of statin. The patients assigned to the ES group are given the basal dose of statin in combination with 10 mg/day of ezetimibe. Data are collected at 0, 12, 26, and 52 weeks. After 12 weeks of treatment, a higher dose of statin is allowed, when necessary, in the ES group, and a higher dose of either statin or ezetimibe is allowed, when necessary, in the DS group. The patients receive none of the following agents during the study: statins other than atorvastatin or pitavastatin, anion-exchanging resin agents, fibrates, nicotinic acids, eicosapentaenoic acid, probucol, and other lipid-lowering agents.

**End points**

The primary endpoint is the percentage change in the level of serum LDL-C from baseline to week 12 of treatment. Along with the LDL-C decrements, percentage of patients who reached the treatment goals (LDL-C <120 mg/dl or <100 mg/dl) was placed at one of the secondary endpoints. Another major secondary endpoint is the effects to the particle size of LDL, whereby measured by amount of small dense low-density lipoprotein (sd-LDL) or remnant-like particle cholesterol (RLP-C). The other secondary endpoints are the high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), triglyceride (TG), high sensitivity C-reactive protein (HS-CRP), and HbA1c, as well as the rate at which the subjects achieve the LDL-C target recommended under the Japanese guideline.

Whereas the effect of the modification will be observed about the patients to whom treatment changes will be applied by not achieving the target level during the extended periods after 12 weeks, long term effects of the regimen of each group will be evaluated as to the subjects without treatment modification in the same period.

**Data measurement**

Samples for sd-LDL are collected at Professor Tsutomu Hirano’s laboratory (Showa University, Tokyo, Japan) and measured by his precipitation method [15]. Samples for RLP-C and HS-CRP are collected and measured in a single laboratory (SRL Inc. Tokyo, Japan). LDL-C values are determined with the Friedelwald’s formula (LDL-C = TC − HDL-C − TG/5). Non-HDL-C values are calculated as TC − HDL-C. The measurements for TC, HDL-C, and TG and routine laboratory tests for parameters such as HbA1C, glucose, AST, ALT, and CK are performed at the participating institutes. Malondialdehyde modified LDL (MDA-LDL) is measured only for patients with CAD, in order to stay within the restrictions set under Japan’s national health insurance policy.

---

![Figure 1 Design scheme for the RESEARCH study.](http://www.lipidworld.com/content/12/1/142)
**Study organization**

The contributors to this study are listed in Table 2. The chair investigator is Professor Teruo Shiba at Toho University Ohashi Medical Center. Study coordination and monitoring are consigned to Nouvelle Plus Co., Ltd. of Tokyo, Japan.

**Statistical design and analysis**

Under the current assumptions, 60 patients need to be enrolled in each group. This number is estimated from the following hypothesis: a doubled statin dose leads to a 11.7% reduction in LDL-C, whereas the addition of ezetimibe leads to a 21.7% reduction in LDL-C (standard deviation: 15%). The significance level is set at 5%, power is set to 90%, and the follow-up ratio is estimated to be 80%

About the end points, differences between the two groups for categorical variables will be assessed using the χ²-test, and continuous variables will be evaluated using the Wilcoxon test. The Wilcoxon signed-rank test will be used to assess the difference in parameters before and after treatment within each group. Significance is set at a p value of less than 0.05 (2-sided) in all analyses. All data will be analyzed using Stata® version 12.1 (Stata Corp LP., Texas, USA).

**Interim results**

Informed consent was obtained from 119 patients at 16 institutes in Japan over the period from July 2009 to June 2012. The recruiting period was initially set at 2 years, but extended to 3 years based on the progress of subject registration. After excluding 10 patients who ceased to conform with the entry criteria or who canceled their consent, 109 patients were randomly assigned to two treatment groups: the DS group (n = 56) and the ES group (n = 53).

The profile of basal treatment was as follows: none (n = 24), oral treatment (n = 58), injection treatment (n = 27) including single treatment of insulin (n = 9) and GLP-1 receptor agonist (n = 2). Totally 74 patients was taking some sort of oral Antidiabetic agents. The number of patients taking each class of agents was 19 for thiazolidinedione (TZD), 36 for sulfonylurea (SU), 40 for biguanide (BG), 21 for α-glucosidase inhibitor (α-GI), 26 for dipeptidyl peptidase IV (DPP-4) inhibitors, and 7 for glinides.

There were no significant differences between the two groups in gender or in the percentages of subjects with a smoking habit, hypertension, hypertriglyceridemia, hypo-HDL-cholesterolemia, chronic kidney disease, history of stroke, history of CAD, or family history of CAD (Table 3). Likewise, there were no significant differences between the groups in age or the levels of TC, TG, HDL-C, LDL-C, non-HDL-C, RLP-C, MDA-LDL, apolipoprotein (apo)-A1, apo-E, fasting glucose, fasting insulin, ALT, AST, γ-GTP, CK, creatinine, HbA1C, or HS-CRP. There were significant but slight differences between the groups in the values of apo-B and sd-LDL (Table 4). We think the randomization was quite successful. As the participant institutes mainly engage in outpatient care for diabetes.

---

**Table 2 Members of the RESEARCH Study Group**

| Investigator        | Institute                                           |
|---------------------|-----------------------------------------------------|
| Teruo Shiba         | Toho University Ohashi Medical Center               |
| Akira Tanaka        | Mitsui Memoral Hospital                             |
| Tsutomu Hirano      | Kagawa Nutrition University, Nutrition Clinic      |
| Tsutomu Yamazaki    | Showa University School of Medicine                 |
| Mitsunobu Kawamura  | The University of Tokyo Hospital                    |
| Takahide Kohro      | Tokyo Teishin Hospital                              |
| Takeshi Inazawa     | Graduate School of Medicine, The University of Tokyo |
| Motoki Tagami       | Kashiwa City Hospital                               |
| Masao Omura         | Sanraku Hospital, Life-style related Disease Clinic |
| Motoyoshi Tsujino   | Yokohama Rosai Hospital                             |
| Takayuki Watanabe   | Tokyo Metropolitan Tama Medical Center              |
| Toshiyuki Horiuchi  | Yokohama City Minato Red Cross Hospital             |
| Toru Hiyoshi        | Toshima Hospital                                     |
| Nobuo Sekine        | Japanese Red Cross Medical Center                   |
| Rina Chin           | Tokyo Kosei Nenkin Hospital                         |
| Keiko Ashidate      | Tokyo Kyosai Hospital                               |
| Yasumichi Mori      | Toranomonon Hospital                                |
subjects with a history of cardiovascular disease were rather rare. The HbA1c value (7.20% in total) was not excellent, but slightly better than that in JDCS [2].

Discussion
When a patient on statins fails to attain good control of LDL-C, a doubling of the statin dose or the addition of ezetimibe seems to be a strong choice for general practitioners. Compared to statins alone, the co-administration of ezetimibe with statins has previously been shown to produce significant incremental reductions in the plasma levels of LDL-C in the general population [16-19]. Since diabetics with hyper-LDL-cholesterolemia are shown to be at high risk for CV events [20] and only around half of diabetic patients meet the LDL-C goal both in the U.S. [21] and in Japan [22], we focused on T2DM patients who were unable to attain the target LDL-C values proposed under the Japanese guideline even when receiving regular doses of strong statins in accordance with the recommendations under Japan’s national health insurance policy. We are thus comparing the LDL-C-lowering effect of a double dose of a strong statin and a regular dose of a strong statin plus ezetimibe in diabetic patients.

Simultaneously, we focus on the particle size changes of LDL-C that may reflect the difference in the mechanisms of these agents which reduce amount of LDL-C. Especially, small-dense low-density lipoprotein (sd-LDL) is recently recognized to be an independent cardiovascular risk marker, presenting as the change in LDL particle size. We evaluated the difference of these two treatments via the major secondary endpoint.

Two earlier reports have compared the effects of co-administration of ezetimibe with a high dose of a standard statin (20 mg of simvastatin plus 10 mg of ezetimibe) with the effects of a double dose of a prescribed standard statin (40 mg of simvastatin in T2DM patients who had been treated with 20 mg of simvastatin). In both of these studies, the mean percent reductions in LDL-C from baseline were significantly greater in the ezetimibe-plus-simvastatin group than in the double-dose simvastatin group [23,24]. In RESEARCH we are looking at the effect of add-on ezetimibe with a strong statin compared to the effect of a double dose of a strong statin. We are also looking at ethnic differences among diabetic patients to analyze whether differences

| Table 3 Patient backgrounds, categorical variables |
|-----------------------------------------------|
| Number of cases | Double dose of statin | Statin + ezetimibe | p value |
|-----------------|-----------------------|-------------------|--------|
| n = 56 | | n = 53 | |
| Male | % | 57.1 | 58.5 | 0.887 |
| Smoking | % | 23.6 | 25.0 | 0.869 |
| Family history of CAD | % | 9.3 | 9.6 | 0.950 |
| Hypertension | % | 67.9 | 58.5 | 0.311 |
| Hypertriglyceridemia | % | 34.5 | 41.5 | 0.456 |
| CKD | % | 16.1 | 9.4 | 0.301 |
| Low HDL-C | % | 3.6 | 7.5 | 0.363 |
| History of stroke | % | 3.6 | 0.0 | 0.169 |
| History of CAD | % | 10.7 | 15.1 | 0.495 |

The data were assessed using the $\chi^2$-test. CAD: coronary artery disease.

| Table 4 Baseline data on the patients, continuous variables |
|----------------------------------------------------------|
| Double dose of statin | Statin + ezetimibe | p value |
|-----------------------|-------------------|--------|
| mean ± sd | mean ± sd | n | n | |
| age | 62.6 ± 9.5 | 56 | 61.7 ± 11.1 | 53 | 0.4949 |
| TC | 218.2 ± 27.2 | 56 | 212.5 ± 30.1 | 53 | 0.3567 |
| TG | 161.9 ± 88.3 | 56 | 146.7 ± 95.2 | 53 | 0.1803 |
| HDL-C | 54.7 ± 9.6 | 56 | 56.7 ± 15.2 | 53 | 0.9734 |
| LDL-C | 135.2 ± 22.6 | 56 | 130.6 ± 19.2 | 53 | 0.5463 |
| non-HDL-C | 163.6 ± 25.7 | 56 | 155.9 ± 26.9 | 52 | 0.1133 |
| RLP-C | 6.3 ± 3.9 | 56 | 6.1 ± 4.8 | 52 | 0.4756 |
| apo A1 | 46.6 ± 16.6 | 44 | 44.2 ± 19.2 | 40 | 0.3288 |
| apo B | 111.4 ± 18.2 | 44 | 101.8 ± 16.5 | 40 | 0.0152 |
| apo E | 4.1 ± 0.9 | 44 | 3.8 ± 1.0 | 40 | 0.1604 |
| MDA-LDL | 157.0 ± 62.0 | 12 | 112.6 ± 27.7 | 9 | 0.0549 |
| sd-LDL | 52.2 ± 17.9 | 56 | 46.2 ± 16.0 | 52 | 0.0484 |
| Fasting glucose | 132.7 ± 32.5 | 56 | 141.5 ± 33.1 | 53 | 0.1108 |
| Fasting insulin | 10.9 ± 7.0 | 35 | 13.8 ± 12.5 | 28 | 0.5381 |
| ALT | 23.6 ± 10.9 | 56 | 24.7 ± 12.5 | 53 | 0.8318 |
| AST | 23.1 ± 12.1 | 52 | 23.7 ± 12.2 | 49 | 0.8541 |
| γ-GTP | 30.2 ± 21.7 | 53 | 28.6 ± 26.6 | 47 | 0.3248 |
| CK | 116.7 ± 58.2 | 54 | 122.5 ± 88.3 | 51 | 0.9642 |
| Creatinine | 0.81 ± 0.28 | 56 | 0.79 ± 0.24 | 51 | 0.9627 |
| HbA1C | 7.15 ± 1.32 | 56 | 7.25 ± 0.64 | 53 | 0.6294 |
| hs-CRP | 1114 ± 1493 | 56 | 922 ± 1119 | 51 | 0.6025 |

The data were evaluated using the Wilcoxon test.
in dietary habits, lifestyles, or physiological reactions influence the atherogenic properties of serum lipid profiles. The clinical backgrounds of the diabetic patients in the earlier studies have also differed. One study followed diabetic patients treated with thiazolidinediones [23], while the other enrolled only diabetic patients with a history of CAD [25]. Another study compared 80 mg of atorvastatin versus 40 mg of atorvastatin plus 10 mg of ezetimibe in T2DM patients who had been treated with 40 mg of atorvastatin alone [25]. In that study, the mean percent reduction in LDL-C from baseline after 6 weeks of treatment was greater in the atorvastatin-plus-ezetimibe group (27%) than in the double-atorvastatin group (10%). Like us they used a strong statin, but unlike us they used atorvastatin, administered at super-high doses, and enrolled patients of variable races. Additionally, their patients were T2DM, metabolic syndrome without T2DM, or subjects with neither metabolic syndrome nor T2DM, hence their analysis on T2DM was post hoc and insufficient to show statistical significance. Our study is prospective and our targets are exclusively T2DM patients on a regular course of strong statins who nonetheless have failed to achieve the LDL-C target recommended under the Japanese guideline. It remains to be seen whether a double dose of strong statins in those patients is more effective than a regular dose of strong statins with ezetimibe, or vice versa. Few reports have addressed this controversial issue, especially in Japan. According to a single center, crossover study from Japan on type-2 diabetes patients or IGT (impaired glucose tolerance) with CAD, co-administration of ezetimibe was superior to a double dose of strong atorvastatin [26]. Yet in another report from Japan described in Japanese literature, treatment with ezetimibe plus pitavastatin brought about more or less the same LDL-C reduction as a double dose of pitavastatin.

We can reasonably hypothesize that a dual therapy of ezetimibe and statins has an edge in lowering LDL-C in T2DM patients, given that these agents affect serum LDL-C level through different mechanisms, one via reduction of intestinal cholesterol absorption, the other via a mighty inhibition of hepatic cholesterol synthesis. It would also be of clinical value to assess how the co-administration of ezetimibe with statins affects the atherogenic lipid profile in diabetic patients. None of the abovementioned studies assessed the effect on sd-LDL, a strong risk factor for CAD [15,27], or on RLP-C, an independent cardiovascular disease risk factor [28]. Ezetimibe therapy is reported to reduce RLP-C in Japanese patients with hyper-LDL-cholesterolemia [29]. Ezetimibe affects the size of LDL particles and reduces the concentration of sd-LDL in T2DM patients [30]. Studies comparing the effects of these two treatments collaterally on the apolipoproteins revealed no differences in the effects on apo A1, apo C3, or apo E, whereas co-administration of ezetimibe with statins significantly decreased apo B, the apo found in non-HDL lipoproteins [19,25].

Our study will be the first prospective, parallel-group, multicenter comparison between a double dose of a strong statin and the combination of ezetimibe plus a strong statin for T2DM patients in actual outpatient clinics (i.e., patients receiving various treatments for glycemic control) who take strong statins but nonetheless fail to achieve the LDL-C target recommended under the Japanese guideline. The patients receiving ezetimibe–plus-statin regimen are expected to show significant reductions in the levels of LDL-C, Non-HDL-C, sd-LDL, and apo-B, and to achieve the LDL-C target recommended under the guideline at a high rate. The RESEARCH study is a necessary step to collect reliable evidence for diabetologists, cardiologists, and general practitioners.

Competing interests
The other authors declare they have no competing interests.

Authors’ contributions
TS is responsible for overall design and registry. TI is assigned to the study design and writing this paper. MK, MT, AT, and YM also contribute to the study design. KS, RI, TK contribute to the study practice including the recruitment of the subjects. TH is in charge of the measurement of sd-LDL. TK and TY are involved in data analysis. All authors read and approved the final manuscript.

Acknowledgements
This study was supported by research grants from Japan Vascular Disease Research Foundation.

Disclosure
Tero Shiba receives honoraria from Shionogi & Co., Ltd., Pfizer Japan Inc., Merck Sharp & Dohme (MSD), Kowa Company, Ltd., and Daiichi Sankyo Company Limited. Tsutomu Yamazaki receives research supports and honoraria from Merck Sharp & Dohme (MSD), Pfizer Japan Inc., Kowa Company, Ltd., Shionogi & Co., Ltd., and AstraZeneca KK, and receives honoraria from Bayer Holding Ltd. and Daiichi Sankyo Company Limited. Akira Tanaka receive research supports from Daiichi Sankyo Company Limited and honoraria from Merck Sharp & Dohme (MSD) and Kewpie Corporation. Honoraria from Bayer Holding Ltd. and Merck Sharp & Dohme (MSD). Takahide Kohro receives research support from AstraZeneca KK and honoraria from Merck Sharp & Dohme (MSD).

Author details
1Kashiwa City Hospital, Chiba, Japan. 2Toho University Ohashi Medical center, Tokyo, Japan. 3Jichi Medical University, Tochigi, Japan. 4Japanese Red Cross Medical Center, Tokyo, Japan. 5Showa University School of Medicine, Tokyo, Japan. 6Tokyo Teishin Hospital, Tokyo, Japan. 7Sanraku Hospital, Life-style related Disease Clinic, Tokyo, Japan. 8Kagawa Nutrition University, Nutrition Clinic, Tokyo, Japan. 9Toranomon Hospital, Tokyo, Japan. 10The University of Tokyo Hospital, Tokyo, Japan. 11Mitsui Memorial Hospital, Tokyo, Japan.

Received: 17 July 2013 Accepted: 26 September 2013 Published: 5 October 2013

References
1. Ministry of Health, Labor and Welfare (Japan). Report of National Health and Nutrition Surveillance. 2010.
2. Sone H, Tanaka S, Japan Diabetes Complications Study Group, et al: Serum level of triglycerides is a potent risk factor comparable to LDL.
cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: sub analysis of the Japan diabetes complications study (JDCS). J Clin Endocrinol Metab 2011, 96:3448–56.

3. Doi Y, Ninomiya T, Hata J, et al. Impact of glucose tolerance status on development of ischemic stroke and coronary heart disease in a general Japanese population: the Hisayama study. Stroke 2010, 41:203–9.

4. Nakamura H, Arakawa K, MEGA Study Group, et al. Primary prevention of cardiovascular disease with Pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006, 368:1155–63.

5. Heart Protection Study Collaborative Group: MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:1623–7.

6. Sever PS, Dahlen B, Poulsen NR, Wedel H, Beesons G, Caufield M, Collins R, Kjeldsen SE, Kristinsson A, McNees GT, ASCOT Investigators, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial-lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1499–515.

7. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349–1357.

8. Cholesterol Treatment Trialists’ (CTT) Collaboration: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670–81.

9. Altman SW, Davis HR Jr, Zhu LJ, et al. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 2004, 303:201–4.

10. Garcia-Calvo M, Lisnock J, Bull HG, Davidson MH, McGarry T, Bettis R, Hirano T, Ito Y, Koba S, Toyoda M, et al. Diagnostic criteria for dyslipidemia. Executive summary of Japan Atherosclerosis Society (JAS) Committee for Atherosclerotic Cardiovascular Diseases for Japanese. J Atheroscler Thromb 2003, 10:233–40.

11. Phan BA, Dayspring TD, Toth PP: Niemann-Pick C1-Like 1 (NPC1L1). Vasc Health Risk Manag 2007, 3:331–340.

12. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of heart and renal protection): a randomised placebo-controlled trial. Lancet 2011, 377:2181–2192.

13. UMIN-CTR. https://uploadumimncat/gi/open-bin/ctt/ctt.cgi?function=brows&action=brows&ps=summary&recno=R000003155&language=J.

14. Teramoto T, Sasaki J, Japan Atherosclerosis Society (JAS) Committee for Epidemiology and Clinical Management of Atherosclerosis, et al, et al. Inclusion in PubMed, CAS, Scopus and Google Scholar

15. Hirano T, Ito Y, Koba S, Toyoda M, et al. Clinical significance of small dense low-density lipoprotein cholesterol levels determined by the simple precipitation method. Arterioscler Thromb Vasc Biol 2004, 24:558–63.

16. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe co administered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002, 40:2125–2134.

17. Ballantyne CM, Houri J, Notarbartolo A, et al. Effects of ezetimibe co administered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003, 107:2409–2415.

18. Kerzner B, Corbell J, Sharp S, et al. Efficacy and safety of ezetimibe co administered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003, 91:418–424.

19. Melani L, Mills R, Hassman D, et al. Efficacy and safety of ezetimibe co-administered with Pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J 2003, 24:717–728.

20. Turner RC, Mills H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS). BMJ 1998, 316:1294–81.

21. Stark Casagrande S, Fradkin JE, Saydah SH, et al. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010. Diabetes Care 2013, 36:8:2271–9.

22. Mabuchi YH, Inazu A, Higashikata T, et al. The current status of medicinal therapy for hyperlipidemia-Kinazawa lipid assessment survey (K-LAS) (in Japanese). Prog Med 2000, 20:1629–1639.

23. Gaudiani LM, Lewin A, Meneghini L, et al. Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients. Diabetes Obes Metab 2005, 7:88–97.

24. Bardini G, Gioda CB, Pontieri AE, et al. Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study). Cardiovasc Diabetol 2010, 9:20.

25. Conard S, Bays H, Leiter LA, et al. Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither. Diabetes Obes Metab 2010, 12:210–8.

26. Umemura Y, Watarai M, Ishii H, et al. Atorvastatin 10 mg plus ezetimibe 10mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease. J Cardiol 2012, 59:50–6.

27. Hirayama S, Mida T. Small dense LDL: an emerging risk factor for cardiovascular disease. Clin Chim Acta 2010, 414:215–24.

28. Varbo A, Bensen M, Tybjaerg-Hansen A, et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013, 61:427–36.

29. Kawagoe Y, Hattori Y, Nakano A, et al. Comparative study between high-dose Fluvastatin and low-dose Fluvastatin and ezetimibe with regard to the effect on endothelial function in diabetic patients. Endocr J 2011, 58:171–5.

30. Sharma SB, Gang S. Small dense LDL: risk factor for coronary artery disease (CAD) and its therapeutic modulation. Indian J Biochem Biophys 2012, 49:77–85.

Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit